Data Sources: Fourteen electronic databases were searched, namely Cochrane Controlled Trials Register, CINAHL (Cumulative Index to Nursing & Allied Health Literature), ERIC (Education Resources Information Center) PsycLit, Dissertation Abstracts, Medline, Embase, Social Science Citation Index, Science Citation Index, Social Psychological Educational Criminological Trials Register, EconLit, Sociological Abstracts, Index to Scientific and Technical Proceedings, and National Research Register. Literature reviews and meta-analyses were inspected for eligible trials and two journals (Public Opinion Quarterly and American Journal of Epidemiology) were searched by hand.
Study Selection: Studies included were randomised controlled trials of methods to increase response rates to postal questionnaires.
Data Extraction And Synthesis: Data describing trial participants, intervention, number of individuals randomised to intervention and comparison groups, and allocation concealment was extracted. For each strategy, pooled odds ratios and 95% confidence intervals in a random-effects model were estimated. Evidence for selection bias was assessed using Egger's weighted regression method, Begg's rank correlation test and funnel plots. Heterogeneity in trial odds ratios was assessed using a chi-square test at a 5% significance level and the degree of inconsistency between trial results was quantified using the I(2) statistic (The I(2) statistic measures the proportion of the variation across studies that is because of heterogeneity. It is calculated by dividing the heterogeneity chi-square minus the number of degrees of freedom by the heterogeneity chi-square, and then multiplying by 100.).
Results: From 372 eligible trials that were included, 98 different ways of increasing response rates to postal questionnaires were evaluated. For 62 of these strategies, the combined trials included over 1000 participants. There was substantial heterogeneity in the trial results from half of the strategies. Strategies found to response are shown in table 1, while three strategies were found to decrease response, questionnaire included questions of a sensitive nature (odds ratio 0.94, 95% CI 0.88-1.00; heterogeneity P =0.51; I(2) 0%), questionnaires began with the most general questions (odds ratio 0.80, 95% CI 0.67-0.96; heterogeneity Not calculated), Participants were offered the opportunity to opt out of the study (odds ratio 0.76, 95% CI 0.65-0.89; heterogeneity P =0.46, I2 0%).
Conclusions: Health researchers using postal questionnaires can increase response rates using the strategies shown to be effective in this systematic review.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1038/sj.ebd.6400499 | DOI Listing |
J Inflamm Res
January 2025
Precision Medicine Laboratory, School of Medical Technology and Engineering, Henan University of Science and Technology, Luoyang, People's Republic of China.
Ovarian cancer (OC) remains one of the most lethal gynecological malignancies, largely due to its late-stage diagnosis and high recurrence rates. Chronic inflammation is a critical driver of OC progression, contributing to immune evasion, tumor growth, and metastasis. Inflammatory cytokines, including IL-6, TNF-α, and IL-8, as well as key signaling pathways such as nuclear factor kappa B (NF-kB) and signal transducer and activator of transcription 3 (STAT3), are upregulated in OC, promoting a tumor-promoting environment.
View Article and Find Full Text PDFFront Immunol
January 2025
Department of Head and Neck Surgery, National Hospital Organization Kyushu Cancer Center, Fukuoka, Fukuoka, Japan.
Background: Nivolumab paved a new way in the treatment of patients with recurrent or metastatic (RM) head and neck squamous cell carcinoma (RM-HNSCC). However, the limited rates of long-term survivors (< 20%) demand a robust prognostic biomarker. This nationwide multi-centric prospective study aimed to identify a plasma exosome (PEX) mRNA signature, which serves as a companion diagnostic of nivolumab and provides a biological clue to develop effective therapies for a majority of non-survivors.
View Article and Find Full Text PDFWorld J Clin Oncol
January 2025
Department of Oncology, Xiyuan Hospital of China Academy of Chinese Medical Sciences, Beijing 100091, China.
Background: Patients with mutant metastatic colorectal cancer (mCRC) have a low incidence rate, poor biological activity, suboptimal response to conventional treatments, and a poor prognosis. In the previous cohort study on mCRC conducted by our team, it was observed that integrated Chinese and Western medicine treatment could significantly prolong the overall survival (OS) of patients with colorectal cancer. Therefore, we further explored the survival benefits in the population with mutant mCRC.
View Article and Find Full Text PDFCrohns Colitis 360
January 2025
Division of Digestive Diseases and Nutrition, Department of Medicine, University of Kentucky College of Medicine, Lexington, KY, USA.
Background: Despite advancements in the therapeutic armamentarium for Crohn's disease (CD), biologic and small molecule monotherapies are associated with sub-optimal response and remission rates. Utilizing dual biologic therapy (DBT) holds the potential to increase efficacy in the treatment of refractory or partially responsive CD. Evidence pertaining to this strategy remains limited.
View Article and Find Full Text PDFGastroenterol Rep (Oxf)
January 2025
Department of Health Sciences, University of Piemonte Orientale, Novara, Italy.
Intrahepatic cholangiocarcinoma (iCCA) is an aggressive liver malignancy that arises from second-order biliary epithelial cells. Its incidence is gradually increasing worldwide. Well-known risk factors have been described, although in many cases, they are not identifiable.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!